- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LYTIX BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 27.08. | Earnings Call Transkript: Lytix Aktie steigt nach positivem FDA-Signal für Q2 2026 | 2 | Investing.com Deutsch | ||
| 27.08. | LYTIX BIOPHARMA ASA: Lytix Biopharma Q2 2026: Marking Defining Milestone | 1 | Cision News | ||
| 27.08. | LYTIX BIOPHARMA ASA: FDA Feedback Clears Path to Registrational Phase III Trial for Ruxotemitide (LTX-315) in Patients with Resectable High-Risk Melanoma | 2 | Cision News | ||
| 26.08. | LYTIX BIOPHARMA ASA: Lytix to Partner with Leading Investigator on ALETTA Study Testing Ruxotemitide in Combination with Ipilimumab and Nivolumab in Early-stage Resectable Melanoma | 1 | Cision News | ||
| 21.08. | LYTIX BIOPHARMA ASA: Lytix Biopharma: Invitation to the Q2 2026 Results Presentation | 2 | Cision News | ||
| 18.08. | LYTIX BIOPHARMA ASA: Lytix Biopharma Strengthens Business Development Leadership with Appointment of Timothy Herpin as Chief Business Officer | 1 | Cision News | ||
| 01.06. | LYTIX BIOPHARMA ASA: Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab | 1 | Cision News | ||
| 21.05. | LYTIX BIOPHARMA ASA: Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances | 2 | Cision News | ||
| 15.05. | LYTIX BIOPHARMA ASA: Lytix Biopharma: Invitation to the Q1 2026 Results Presentation | 1 | Cision News | ||
| 06.05. | LYTIX BIOPHARMA ASA: New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma | 19 | Cision News | ||
| 21.04. | Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026 | 1 | Cision News | ||
| 21.04. | Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma | 7 | Cision News | ||
| 16.04. | Lytix Biopharma ASA - Conversion to public limited liability company and name change registered | 1 | Cision News | ||
| 14.04. | Lytix Biopharma AS: Minutes from Annual General Meeting | 1 | Cision News | ||
| 09.04. | Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS | 1 | Cision News | ||
| 07.04. | Lytix Biopharma Names Renée Christine Amundsen COO With Immediate Effect | 1 | RTTNews | ||
| 07.04. | LYTIX BIOPHARMA AS: Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth | 1 | Cision News | ||
| 25.03. | Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026 | 6 | Cision News | ||
| 24.03. | Lytix Biopharma AS: Annual Report for 2025 | 2 | Cision News | ||
| 18.03. | LYTIX BIOPHARMA AS: Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026 | 4 | Cision News |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LINEAGE CELL THERAPEUTICS | 0,936 | +0,11 % | Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call | ||
| NOVOGENIA | 7,200 | +9,09 % | EQS-News: Novogenia AG: Novogenia setzt neue Maßstäbe mit US-Einführung des erweiterten Methylierungstests MGT Plus und baut internationales Produktportfolio aus | EQS-News: Novogenia AG
/ Schlagwort(e): Produkteinführung
Novogenia setzt neue Maßstäbe mit US-Einführung des erweiterten Methylierungstests MGT Plus und baut internationales... ► Artikel lesen | |
| BIOAFFINITY TECHNOLOGIES | 15,170 | -0,65 % | Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,600 | -0,03 % | Summit Therapeutics Stock Rises 11% | ||
| QIAGEN | 37,435 | -0,09 % | Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit | ||
| TARSUS PHARMACEUTICALS | 90,84 | +0,07 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care | Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt's disease, a potentially blinding disease with no FDA-approved... ► Artikel lesen | |
| TYRA BIOSCIENCES | 28,650 | 0,00 % | Tyra Bio rises on upcoming mid-stage trial readout for bladder cancer drug | ||
| RECURSION PHARMACEUTICALS | 3,635 | +0,14 % | Can RXRX's Pipeline Expansion Strengthen Its Long-Term Growth Outlook? | ||
| PRAXIS PRECISION MEDICINES | 352,42 | +0,17 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| VIR BIOTECHNOLOGY | 11,385 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| VERA THERAPEUTICS | 35,890 | 0,00 % | Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| MODERNA | 125,24 | -0,03 % | BioNTech Aktie: Nach dem Moderna-Rausch folgt der Kater | Bei der BioNTech Aktie ging es in den vergangenen Tagen wild zu. Erst schwamm das an der NASDAQ notierte Papier auf der Welle positiver Moderna-Nachrichten nach oben und fuhr hohe Gewinne ein, dann... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,270 | -0,04 % | Dyne to present preclinical data on four DMD therapies | ||
| RELAY THERAPEUTICS | 19,060 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,48 | +0,08 % | Can KT-621 Mark a Turning Point for Kymera Therapeutics? |
Das Unternehmen LYTIX BIOPHARMA ASA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,11 % bei einem Aktienkurs von 0,744 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYTIX BIOPHARMA ASA finden Sie auf Wallstreet Online.